unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma with PD-L1 expression. In esophageal cancer, the agent is also approved by regulatory agencies in combination with platinum- and ...

Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Phase 3 trial showed Keytruda-Lenvima improves progression-free survival and response rates in HER2-negative ... is a rare type of cancer that occurs in the esophagus, the passageway that ...

Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small Chinese study showed.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

Patients who traveled to high-volume centers for esophagectomy experienced better outcomes than those who sought treatment ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma ... Patients had no known HER2 positivity and an ECOG performance status of 0 or 1. Study enrollment occurred at 175 ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...